Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology

Peter Seferović; Dimitrios Farmakis; Antoni Bayes-Genis; Tuvia Ben Gal; Michael Böhm; Ovidiu Chioncel; Roberto Ferrari; Gerasimos Filippatos; Loreena Hill; Ewa Jankowska; Mitja Lainscak; Yuri Lopatin; Lars H. Lund; Alexandre Mebazaa; Marco Metra; Brenda Moura; Giuseppe Rosano; Thomas Thum; Adriaan Voors; Andrew J.S. Coats

doi:10.1002/ejhf.2575

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology

Peter Seferović, Dimitrios Farmakis, Antoni Bayes-Genis, Tuvia Ben Gal, Michael Böhm, Ovidiu Chioncel, Roberto Ferrari, Gerasimos Filippatos, Loreena Hill, Ewa Jankowska, Mitja Lainscak, Yuri Lopatin, Lars H. Lund, Alexandre Mebazaa, Marco Metra, Brenda Moura, Giuseppe Rosano, Thomas Thum, Adriaan Voors, Andrew J.S. Coats

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Knowledge on risk predictors of incident heart failure (HF) in patients with type-2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognised as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established CV biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and CV events in patients with T2D and in those with established HF and T2D.

Original language	English
Pages (from-to)	1162-1170
Number of pages	9
Journal	European Journal of Heart Failure
Volume	24
Issue number	7
Early online date	15 Jun 2022
DOIs	https://doi.org/10.1002/ejhf.2575
Publication status	Published online - 15 Jun 2022

Bibliographical note

Funding Information: P.S.: honorarium for lectures from Servier, AstraZeneca, Respicardia, Menarini; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis, Vifor Pharma and Roche Diagnostics. D.F.: lecture or consultation fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo, Novartis and Orion. A.B.G.: lecture honoraria or participated in advisory boards from Abbott, AstraZeneca Boehringer Ingelheim, Novartis, Roche Diagnostics, Vifor. M.B.: supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor Medical, Servier, and Vifor. O.C.: grants from Servier, Vifor Novartis and fees from Boehringer Ingelheim. R.F.: research grants and personal fees from Novartis and Servier, personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici; director of Art Research and Science S.r.l (A.R.S.1). G.F.: participation in committees of trials and registries sponsored by Bayer, Boehringer Ingelheim, Medtronic, Servier, Novartis, and Vifor. E.J.: research grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda and Gedeon Richter. M.L.: personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer. L.H.L.: grants from AstraZeneca,Vifor, Boston Scientific, Boehringer Ingelheim, Novartis; consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier; speakers honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, Novartis; shareholder in AnaCardio. A.M.: personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips, grants and personal fees from Adrenomed, Abbott; grants from 4TEEN4. M.M.: personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, WindTree Therapeutics, as member of Trials' Committees or advisory boards or for speeches at sponsored meetings in the last 3 years. B.M.: advisory or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Ely Lilly, Servier, Novartis, Vifor Pharma. T.T.: founder and shareholder of Cardior Pharmaceuticals GmbH; speaker fees from Novo Nordisk, Boehringer Ingelheim, Sanofi‐Genzyme, Takeda, Amicus Therapeutis, KSLINK. A.V.: research support and/or consulting fees from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics. A.J.S.C.: honoraria and/or lecture fees from Astra Zeneca, Boehringer Ingelheim, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, Viatris, outside of this work in the last 3 years. All other authors have nothing to disclose. Conflict of interest: Publisher Copyright: © 2022 European Society of Cardiology.

Keywords

Diabetes mellitus
Heart failure
Biomarkers
Cardiovascular risk
Cardiovascular prevention

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ejhf.2575

AAMAuthor Accepted Manuscript, 478 KB

Fingerprint

Dive into the research topics of 'Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology'. Together they form a unique fingerprint.

Cite this

Seferović, P., Farmakis, D., Bayes-Genis, A., Gal, T. B., Böhm, M., Chioncel, O., Ferrari, R., Filippatos, G., Hill, L., Jankowska, E., Lainscak, M., Lopatin, Y., Lund, L. H., Mebazaa, A., Metra, M., Moura, B., Rosano, G., Thum, T., Voors, A., & Coats, A. J. S. (2022). Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 24(7), 1162-1170. Advance online publication. https://doi.org/10.1002/ejhf.2575

Seferović, Peter ; Farmakis, Dimitrios ; Bayes-Genis, Antoni et al. / Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology. In: European Journal of Heart Failure. 2022 ; Vol. 24, No. 7. pp. 1162-1170.

@article{686bfbace8a744f98b715e33162213fe,

title = "Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology",

abstract = "Knowledge on risk predictors of incident heart failure (HF) in patients with type-2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognised as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established CV biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and CV events in patients with T2D and in those with established HF and T2D.",

keywords = "Diabetes mellitus, Heart failure, Biomarkers, Cardiovascular risk, Cardiovascular prevention",

author = "Peter Seferovi{\'c} and Dimitrios Farmakis and Antoni Bayes-Genis and Gal, {Tuvia Ben} and Michael B{\"o}hm and Ovidiu Chioncel and Roberto Ferrari and Gerasimos Filippatos and Loreena Hill and Ewa Jankowska and Mitja Lainscak and Yuri Lopatin and Lund, {Lars H.} and Alexandre Mebazaa and Marco Metra and Brenda Moura and Giuseppe Rosano and Thomas Thum and Adriaan Voors and Coats, {Andrew J.S.}",

note = "Funding Information: P.S.: honorarium for lectures from Servier, AstraZeneca, Respicardia, Menarini; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis, Vifor Pharma and Roche Diagnostics. D.F.: lecture or consultation fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo, Novartis and Orion. A.B.G.: lecture honoraria or participated in advisory boards from Abbott, AstraZeneca Boehringer Ingelheim, Novartis, Roche Diagnostics, Vifor. M.B.: supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor Medical, Servier, and Vifor. O.C.: grants from Servier, Vifor Novartis and fees from Boehringer Ingelheim. R.F.: research grants and personal fees from Novartis and Servier, personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici; director of Art Research and Science S.r.l (A.R.S.1). G.F.: participation in committees of trials and registries sponsored by Bayer, Boehringer Ingelheim, Medtronic, Servier, Novartis, and Vifor. E.J.: research grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda and Gedeon Richter. M.L.: personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer. L.H.L.: grants from AstraZeneca,Vifor, Boston Scientific, Boehringer Ingelheim, Novartis; consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier; speakers honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, Novartis; shareholder in AnaCardio. A.M.: personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips, grants and personal fees from Adrenomed, Abbott; grants from 4TEEN4. M.M.: personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, WindTree Therapeutics, as member of Trials' Committees or advisory boards or for speeches at sponsored meetings in the last 3 years. B.M.: advisory or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Ely Lilly, Servier, Novartis, Vifor Pharma. T.T.: founder and shareholder of Cardior Pharmaceuticals GmbH; speaker fees from Novo Nordisk, Boehringer Ingelheim, Sanofi‐Genzyme, Takeda, Amicus Therapeutis, KSLINK. A.V.: research support and/or consulting fees from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics. A.J.S.C.: honoraria and/or lecture fees from Astra Zeneca, Boehringer Ingelheim, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, Viatris, outside of this work in the last 3 years. All other authors have nothing to disclose. Conflict of interest: Publisher Copyright: {\textcopyright} 2022 European Society of Cardiology.",

year = "2022",

month = jun,

day = "15",

doi = "10.1002/ejhf.2575",

language = "English",

volume = "24",

pages = "1162--1170",

journal = "European Journal of Heart Failure",

issn = "1879-0844",

publisher = "Wiley Online Library",

number = "7",

}

Seferović, P, Farmakis, D, Bayes-Genis, A, Gal, TB, Böhm, M, Chioncel, O, Ferrari, R, Filippatos, G, Hill, L, Jankowska, E, Lainscak, M, Lopatin, Y, Lund, LH, Mebazaa, A, Metra, M, Moura, B, Rosano, G, Thum, T, Voors, A & Coats, AJS 2022, 'Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology', European Journal of Heart Failure, vol. 24, no. 7, pp. 1162-1170. https://doi.org/10.1002/ejhf.2575

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology. / Seferović, Peter; Farmakis, Dimitrios; Bayes-Genis, Antoni et al.
In: European Journal of Heart Failure, Vol. 24, No. 7, 15.06.2022, p. 1162-1170.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology

AU - Seferović, Peter

AU - Farmakis, Dimitrios

AU - Bayes-Genis, Antoni

AU - Gal, Tuvia Ben

AU - Böhm, Michael

AU - Chioncel, Ovidiu

AU - Ferrari, Roberto

AU - Filippatos, Gerasimos

AU - Hill, Loreena

AU - Jankowska, Ewa

AU - Lainscak, Mitja

AU - Lopatin, Yuri

AU - Lund, Lars H.

AU - Mebazaa, Alexandre

AU - Metra, Marco

AU - Moura, Brenda

AU - Rosano, Giuseppe

AU - Thum, Thomas

AU - Voors, Adriaan

AU - Coats, Andrew J.S.

N1 - Funding Information: P.S.: honorarium for lectures from Servier, AstraZeneca, Respicardia, Menarini; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis, Vifor Pharma and Roche Diagnostics. D.F.: lecture or consultation fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo, Novartis and Orion. A.B.G.: lecture honoraria or participated in advisory boards from Abbott, AstraZeneca Boehringer Ingelheim, Novartis, Roche Diagnostics, Vifor. M.B.: supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor Medical, Servier, and Vifor. O.C.: grants from Servier, Vifor Novartis and fees from Boehringer Ingelheim. R.F.: research grants and personal fees from Novartis and Servier, personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici; director of Art Research and Science S.r.l (A.R.S.1). G.F.: participation in committees of trials and registries sponsored by Bayer, Boehringer Ingelheim, Medtronic, Servier, Novartis, and Vifor. E.J.: research grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda and Gedeon Richter. M.L.: personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer. L.H.L.: grants from AstraZeneca,Vifor, Boston Scientific, Boehringer Ingelheim, Novartis; consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier; speakers honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, Novartis; shareholder in AnaCardio. A.M.: personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips, grants and personal fees from Adrenomed, Abbott; grants from 4TEEN4. M.M.: personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, WindTree Therapeutics, as member of Trials' Committees or advisory boards or for speeches at sponsored meetings in the last 3 years. B.M.: advisory or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Ely Lilly, Servier, Novartis, Vifor Pharma. T.T.: founder and shareholder of Cardior Pharmaceuticals GmbH; speaker fees from Novo Nordisk, Boehringer Ingelheim, Sanofi‐Genzyme, Takeda, Amicus Therapeutis, KSLINK. A.V.: research support and/or consulting fees from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics. A.J.S.C.: honoraria and/or lecture fees from Astra Zeneca, Boehringer Ingelheim, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, Viatris, outside of this work in the last 3 years. All other authors have nothing to disclose. Conflict of interest: Publisher Copyright: © 2022 European Society of Cardiology.

PY - 2022/6/15

Y1 - 2022/6/15

N2 - Knowledge on risk predictors of incident heart failure (HF) in patients with type-2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognised as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established CV biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and CV events in patients with T2D and in those with established HF and T2D.

AB - Knowledge on risk predictors of incident heart failure (HF) in patients with type-2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognised as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established CV biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and CV events in patients with T2D and in those with established HF and T2D.

KW - Diabetes mellitus

KW - Heart failure

KW - Biomarkers

KW - Cardiovascular risk

KW - Cardiovascular prevention

UR - https://pure.qub.ac.uk/en/publications/biomarkers-for-the-prediction-of-heart-failure-and-cardiovascular

U2 - 10.1002/ejhf.2575

DO - 10.1002/ejhf.2575

M3 - Article

SN - 1879-0844

VL - 24

SP - 1162

EP - 1170

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 7

ER -

Seferović P, Farmakis D, Bayes-Genis A, Gal TB, Böhm M, Chioncel O et al. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2022 Jun 15;24(7):1162-1170. Epub 2022 Jun 15. doi: 10.1002/ejhf.2575

Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this